LIXT
NASDAQ · Biotechnology
Lixte Biotechnology Holdings
$2.95
-0.07 (-2.32%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.59M | 2.67M | 2.41M |
| Net Income | 404.7K | 492.8K | 436.5K |
| EPS | — | — | — |
| Profit Margin | 15.6% | 18.4% | 18.1% |
| Rev Growth | +13.7% | +15.1% | +4.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 8.68M | 11.00M | 11.32M |
| Total Equity | 7.54M | 8.09M | 8.68M |
| D/E Ratio | 1.15 | 1.36 | 1.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 711.7K | 711.0K | 701.7K |
| Free Cash Flow | 315.8K | 252.8K | 287.8K |